End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
730,000 KRW | -0.27% | -5.19% | -3.95% |
May. 31 | Samsung Biologics Aims to Lower Greenhouse Gas Emissions by 2030 | MT |
May. 23 | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
Sales 2024 * | 4,266B 3.09B | Sales 2025 * | 4,931B 3.57B | Capitalization | 51,957B 37.62B |
---|---|---|---|---|---|
Net income 2024 * | 975B 706M | Net income 2025 * | 1,178B 853M | EV / Sales 2024 * | 11.8 x |
Net cash position 2024 * | 1,742B 1.26B | Net cash position 2025 * | 2,750B 1.99B | EV / Sales 2025 * | 9.98 x |
P/E ratio 2024 * |
53.3
x | P/E ratio 2025 * |
45.2
x | Employees | 4,284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
1 day | -0.27% | ||
1 week | -5.19% | ||
Current month | -6.53% | ||
1 month | -6.53% | ||
3 months | -5.68% | ||
6 months | +0.69% | ||
Current year | -3.95% |
Managers | Title | Age | Since |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 730,000 | -0.27% | 51,389 |
24-05-30 | 732,000 | +0.69% | 38,342 |
24-05-29 | 727,000 | -2.42% | 89,242 |
24-05-28 | 745,000 | -1.32% | 52,416 |
24-05-27 | 755,000 | +0.53% | 44,353 |
End-of-day quote Korea S.E., May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.95% | 37.92B | |
-2.29% | 89.38B | |
-13.07% | 32.04B | |
+63.05% | 26.03B | |
-22.14% | 14.14B | |
-7.96% | 12.88B | |
-9.33% | 11.77B | |
-46.33% | 10.85B | |
+5.77% | 8.92B | |
-17.66% | 7.34B |
- Stock Market
- Equities
- A207940 Stock